Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Matrix Capital Management
AddedFeb 13, 2024
UpdatedJun 28, 2026
Matrix Capital Management

Matrix Capital Management

Operating

Matrix Capital Management: A private investment firm specializing in high-conviction tech and life sciences.

Location
Waltham, MA, US
Founded
1999
Firm
Compare
Portfolio
Employees

Investments

ReCode Therapeutics
ReCode Therapeutics

Total Raised

$521.8M

Rounds

6

Series B$50MSeptember 2023
Series B$120MJune 2022
AltPep
AltPep

Total Raised

$76M

Rounds

2

Series B$52.9MJune 2023
Series A$23.1MJanuary 2021
ElevateBio
ElevateBio

Total Raised

$1.2B

Rounds

5

Series D$401MMay 2023
Series C$525MMarch 2021
Monod Bio
Monod Bio

Total Raised

$25M

Rounds

1

Seed$25MAugust 2022
Talos
Talos

Total Raised

$145M

Rounds

3

Series B$105MMay 2022
Koneksa Health
Koneksa Health

Total Raised

$70.6M

Rounds

6

Series C$45MFebruary 2022
Blockdaemon
Blockdaemon

Total Raised

$431.3M

Rounds

10

Series C$207MJanuary 2022
Series B$155MSeptember 2021
Solve Therapeutics
Solve Therapeutics

Total Raised

$126M

Rounds

1

Series A$126MJanuary 2022
Maze Therapeutics
Maze Therapeutics

Total Raised

$381M

Rounds

3

Series Unknown$190MJanuary 2022
Alumis
Alumis

Total Raised

$270M

Rounds

2

Series B$200MJanuary 2022
Pramana
Pramana

Total Raised

$30M

Rounds

1

Series A$30MJanuary 2022
Bardavon Health Innovations
Bardavon Health Innovations

Total Raised

$126.3M

Rounds

6

Series C$90MOctober 2021
GentiBio
GentiBio

Total Raised

$177M

Rounds

2

Series A$157MAugust 2021
Emboline
Emboline

Total Raised

$75M

Rounds

3

Series D$55MMay 2021
Anumana
Anumana

Total Raised

$117.7M

Rounds

4

Series B$60MMay 2021
Series A$25.7MApril 2021
nference
nference

Total Raised

$152.7M

Rounds

7

Series C$66MDecember 2020
Series B$69MJanuary 2020
Palleon Pharmaceuticals
Palleon Pharmaceuticals

Total Raised

$147.6M

Rounds

2

Series B$100MSeptember 2020
Encoded Therapeutics
Encoded Therapeutics

Total Raised

$239.1M

Rounds

3

Series D$135MJuly 2020
VelosBio
VelosBio
Acquired

Total Raised

$202.7M

Rounds

3

Series B$137MJuly 2020